Effects of infantile/prepubertal chronic estrogen treatment and chemical sympathectomy with guanethidine on developing cholinergic nerves of the rat uterus.
The innervation of the uterus is remarkable in that it exhibits physiological changes in response to altered levels in the circulating levels of sex hormones. Previous studies by our group showed that chronic administration of estrogen to rats during the infantile/prepubertal period provoked, at 28 days of age, an almost complete loss of norepinephrine-labeled sympathetic nerves, similar to that observed in late pregnancy. It is not known, however, whether early exposure to estrogen affects uterine cholinergic nerves. Similarly, it is not known to what extent development and estrogen-induced responses in the uterine cholinergic innervation are affected by the absence of sympathetic nerves. To address this question, in this study we analyzed the effects of infantile/prepubertal chronic estrogen treatment, chronic chemical sympathectomy with guanethidine, and combined sympathectomy and chronic estrogen treatment on developing cholinergic nerves of the rat uterus. Cholinergic nerves were visualized using a combination of acetylcholinesterase histochemistry and the immunohistochemical demonstration of the vesicular acetylcholine transporter (VAChT). After chronic estrogen treatment, a well-developed plexus of cholinergic nerves was observed in the uterus. Quantitative studies showed that chronic exposure to estrogen induced contrasting responses in uterine cholinergic nerves, increasing the density of large and medium-sized nerve bundles and reducing the intercept density of fine fibers providing myometrial and perivascular innervation. Estrogen-induced changes in the uterine cholinergic innervation did not appear to result from the absence/impairment of sympathetic nerves, because sympathectomy did not mimic the effects produced by estrogen. Estrogen-induced responses in parasympathetic nerves are discussed, considering the direct effects of estrogen on neurons and on changes in neuron-target interactions.
Richeri
Analía
A
Laboratorio de Biología Celular, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo, Uruguay.
Viettro
Lorena
L
Chávez-Genaro
Rebeca
R
Burnstock
Geoffrey
G
Cowen
Timothy
T
Brauer
M Mónica
MM
D000110:Acetylcholinesterase / Q000378:metabolism; D000818:Animals; D000831:Animals, Newborn; D002352:Carrier Proteins / Q000378:metabolism; D002799:Cholinergic Fibers / Q000201:enzymology / Q000378:metabolism* / Q000648:ultrastructure; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology*; D005260:Female; D006145:Guanethidine; D006651:Histocytochemistry; D026901:Membrane Transport Proteins; D051381:Rats; D017208:Rats, Wistar; D013563:Sympathectomy, Chemical; D013564:Sympathetic Nervous System / Q000254:growth & development / Q000378:metabolism* / Q000648:ultrastructure; D013565:Sympatholytics; D014599:Uterus / Q000254:growth & development / Q000294:innervation*; D050494:Vesicular Acetylcholine Transport Proteins; D033921:Vesicular Transport Proteins
D002352:Carrier Proteins; D026901:Membrane Transport Proteins; C493461:Slc18a3 protein, rat; D013565:Sympatholytics; D050494:Vesicular Acetylcholine Transport Proteins; D033921:Vesicular Transport Proteins; D004958:Estradiol; C007630:estradiol 17 beta-cypionate; D000110:Acetylcholinesterase; D006145:Guanethidine